MedElevator
Войти в исследования Veterinary ophthalmology · 2026
The Impact of Systemic Treatment With Flunixin Meglumine on the Two Antiproteases Alpha-2-Macroglobulin (A2M) and Alpha-1-Antitrypsin (A1AT) in Equine Plasma and Platelet-Rich Fibrin (PRF).
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Scheunemann Kaitlyn R, Jones Katrina E V, Young Kimberly, Zhang Chongben, McGrath Cody, Love Kimberly R, de Linde Henriksen Michala
Аннотация
PURPOSE: To evaluate the effect of flunixin meglumine, a systemic non-steroidal anti-inflammatory drug (NSAID), on the antiproteases, A2M and A1AT, in equine plasma and PRF.
METHODS: A prospective cross-sectional study. Plasma, solid PRF, and liquid PRF were collected from a control-group that included healthy horses not treated with NSAIDs within the last 3 months. The NSAID-group were ophthalmology patients with no systemic inflammatory disease, and all received a full dose of flunixin meglumine (1.1 mg/kg BID PO or IV) for three or more days prior to collection. Samples were collected and prepared using a standardized protocol for plasma and PRF preparation. Concentrations of A2M and A1AT were analyzed with ELISA kits. Statistical analysis with Mann-Whitney U tests and Wilcoxon signed-rank tests was performed using significance set at p < 0.05.
RESULTS: No significant differences were found between the control-group (n = 12) and NSAID-group (n = 12) for any of the blood products (p > 0.05). Plasma had a significantly higher amount of A2M compared to solid and liquid PRF (both p < 0.001). Solid PRF had the highest concentration of A1AT and was significantly higher when compared to liquid PRF (p < 0.001), but not when compared to plasma (p = 0.071).
CONCLUSIONS: The systemic NSAID, flunixin meglumine, does not appear to significantly alter antiprotease concentrations in equine plasma or PRF. Although PRF should not be used as a replacement for plasma, solid PRF may be a good adjunctive therapy for the treatment of keratomalacia due to its high A1AT concentration.
METHODS: A prospective cross-sectional study. Plasma, solid PRF, and liquid PRF were collected from a control-group that included healthy horses not treated with NSAIDs within the last 3 months. The NSAID-group were ophthalmology patients with no systemic inflammatory disease, and all received a full dose of flunixin meglumine (1.1 mg/kg BID PO or IV) for three or more days prior to collection. Samples were collected and prepared using a standardized protocol for plasma and PRF preparation. Concentrations of A2M and A1AT were analyzed with ELISA kits. Statistical analysis with Mann-Whitney U tests and Wilcoxon signed-rank tests was performed using significance set at p < 0.05.
RESULTS: No significant differences were found between the control-group (n = 12) and NSAID-group (n = 12) for any of the blood products (p > 0.05). Plasma had a significantly higher amount of A2M compared to solid and liquid PRF (both p < 0.001). Solid PRF had the highest concentration of A1AT and was significantly higher when compared to liquid PRF (p < 0.001), but not when compared to plasma (p = 0.071).
CONCLUSIONS: The systemic NSAID, flunixin meglumine, does not appear to significantly alter antiprotease concentrations in equine plasma or PRF. Although PRF should not be used as a replacement for plasma, solid PRF may be a good adjunctive therapy for the treatment of keratomalacia due to its high A1AT concentration.